Back to results
US 8,524,669 B2Granted
MUC-1 cytoplasmic domain peptides as inhibitors of cancer
AssigneesDana-Farber Cancer Institute, Inc., Genus Oncology, LLC
InventorsDonald W. Kufe, Surender Kharbanda
Life of this patent
Estimating the term…
Abstract
The invention provides for peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.
Claims26
A method of inhibiting a human Mucin 1 (MUC1)-positive tumor cell in a human subject comprising administering to said subject a MUC1 peptide of at least 6 consecutive human MUC1 residues and no more than 20 consecutive human MUC1 residues and comprising the sequence CQCRRK (SEQ ID NO:
- 4), wherein the amino-terminal cysteine of CQCRRK is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence.
Dependencies are inferred from the claim text.